LOS ANGELES — PASS has debuted a new contact tracing program for Mycoplasma genitalium (Mgen) cases in the adult industry.
The statement by PASS follows:
PASS has launched a new contact tracing program to help mitigate the spread of Mycoplasma genitalium (Mgen) in the adult industry.
With typical testing and treatment of reduced efficacy for Mgen, the tool will enable PASS to target people at the highest risk, and thus minimize the potential of additional transmission. All talent who participate in PASS are required to be tested for Mgen by Oct. 1.
Performers who have received a positive Mgen result can anonymously use this form to identify recent sexual partners. PASS will then reach out to notify them that they have been potentially exposed, and help them get tested, and if needed, treated.
PASS Executive Director Ian O’Brien says the contact tracing program is critical in protecting performers.
“Mgen presents a complex challenge for the adult community, which means we need to be aggressive in confronting its spread. PASS has long used contact tracing to identify, notify, and monitor individuals who may have been exposed to an infectious disease, but we’ve never done something on this scale. With the community’s help, we can quantify and identify risk and begin to more effectively treat Mgen.”
The contact tracing program builds on recent guidance published by PASS.
Filling out this form is entirely anonymous and voluntary. Anyone with questions about the process or protocol can contact PASS at info@passcertified.org.
For more information, visit PASSCertified.org.